核心结合因子相关急性髓系白血病(core-binding factor acute myeloid leukemia，CBF-AML)是AML中较常见的细胞遗传学亚型，其约占AML总数的15% 。CBF-AML主要包括2种遗传学表型：①8号和21号染色体易位t(8；21)(q22；q22)，编码核心结合因子(core-binding factor, CBF)α基因受到破坏，产生 ...

2021年6月16日 · Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t (8;21) (q22;q22) or inv (16) (p13q22)/t...

21号染色体上的遗传物质重组易位，是一类血癌，即核心结合因子- 急性髓系白血病 (CBF-AML)的病因。 约7%的核心结合因子-急性髓系白血病患者的体内出现过此类染色体重组易位现象。 此易位，在医学上被记为 t (8;21)，将21号染色体的 RUNX1 基因的部分遗传物质和8号染色体上的 RUNX1T1 基因（亦被称为 ETO）的部分遗传物质融合在一起。 在人的一生中，此类变异均有可能发生，而且此遗传物质变异现象仅仅出现在特定的细胞里，在医学上被称为体细胞突变，并不 …

CBF molecular aberrations are responsible for approximately 20% of all adult acute myeloid leukemia (AML). Although CBF-AMLs are considered to have relatively good prognosis compared to other leukemia subtypes, they are a heterogeneous group of disorders and modern therapy frequently leads to relapse and the associated morbidity and mortality.

Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. Explore symptoms, inheritance, genetics of this condition.

2021年6月16日 · Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t (8;21) (q22;q22) or inv (16) (p13q22)/t (16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective …

Core-binding factor acute myeloid leukemia (AML) is cytogenetically defined by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), commonly abbreviated as t(8;21) and inv(16), respectively. In both subtypes, the cytogenetic rearrangements disrupt genes that encode subunits of core …

Core-binding factor acute myeloid leukemia (CBF-AML) is caused by specific non-random chromosome translocation or inversion, and has been categorized as an independent cytogenetic type of acute myeloid leukemia (AML). Clinically, CBF-AML is caused by t(8; 21)(q22; q22), and inv(16)(p13.1; q22) or t(16; 16)(p13.1; q232), and is generally divided ...

cbf-aml是伴有aml1-eto和cbfb-myh11两种重现性细胞遗传学异常的aml总称，儿童患病率略高于成人 。cbf-aml对化疗敏感，第1个疗程诱导治疗cr率可达90%以上，5年os率可高于80%，是一种预后较好的aml亚型 [1-3] 。本研究中cbf-aml患儿第1个疗程诱导治疗cr率为97%，中位随访58个月 ...

2022年4月7日 · Core-binding factor acute myeloid leukemia (CBF-AML) has been associated with relatively better prognosis following intensive AML directed therapy,...